06:38 AM EDT, 03/19/2026 (MT Newswires) -- Greenwich LifeSciences ( GLSI ) said Thursday that it has initiated new clinical sites in the US for a phase 3 trial of GLS-100, a fast-track-designated immunotherapy to prevent breast cancer recurrences.
The clinical trial has recently been activated at City of Hope network sites in southern California, Arizona, Atlanta, and Illinois.